|
Research Management and Support
|
RMS2010 [E]
|
$345,370,533
|
N/A
|
National Cancer Institute
|
|
Children's Oncology Group Chair's Grant
|
5U10CA098543-08
|
$26,966,030
|
ADAMSON, PETER
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Role of Physical Properties in Pharmacokinetics, Biodistribution and Tumor Uptake
|
1F31CA150566-01
|
$37,769
|
Adjei, Isaac
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
1R01CA140368-01A1
|
$313,408
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Prostate Cancer Prevention and Treatment by Silibinin
|
5R01CA102514-07
|
$332,920
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
The CCNY/MSKCC Partnership for Research, Training and Outreach
|
3U54CA137788-03S1
|
$200,000
|
Ahles, Tim
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
The CCNY/MSKCC Partnership for Research, Training and Outreach
|
5U54CA137788-03
|
$1,506,183
|
Ahles, Tim
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Participation in the Eastern Cooperative Oncology Group
|
2U10CA107868-07
|
$235,766
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
|
1R01CA138671-01A1
|
$319,550
|
Ajani, Jaffer
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus Cancer
|
5R21CA129906-02
|
$183,294
|
Ajani, Jaffer
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Biodegradable Polymeric Nanosphere Drug Delivery System For Cancer Chemotherapy
|
5SC2CA138179-03
|
|
AKALA, EMMANUEL
|
HOWARD UNIVERSITY
|
|
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog
|
5R01CA120552-05
|
$248,463
|
AKPORIAYE, EMMANUEL
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Molecular Interaction Maps and Analysis of Bioregulatory Networks
|
ZIA BC 010562
|
$94,000
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-14
|
$1,182,811
|
Albelda, Steven
|
UNIVERSITY OF PENNSYLVANIA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-32S1
|
$100,000
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-32S2
|
$143,893
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-32S3
|
$100,000
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
5P30CA023074-32
|
$4,161,905
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Novel Targeted Therapeutics for Cental Nervous System Malignancies
|
5R01CA112519-05
|
$340,769
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
Protein Kinase C and GSTP1 interactions in glioma drug resistance
|
5R01CA127872-03
|
$323,700
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
Cdk-2 Independent role of cyclin E in Cell survival
|
5R01CA127264-02
|
$325,302
|
Almasan, Alexandru
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Rational Design and Clinical Development of Shepherdin: A Novel Anti-Cancer Agent
|
5R01CA118005-02
|
$341,338
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Lung cancer heterogeneity and its impact on drug resistance.
|
1R01CA133253-01A2
|
$500,950
|
ALTSCHULER, STEVEN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
Exploiting altered glucose utilization in Bcr-Abl+ Leukemia
|
1F31CA157166-01
|
$28,740
|
Alvarez-Calderon, Francesca
|
UNIVERSITY OF COLORADO DENVER
|
|
Therapeutic approaches that target cancer cell metabolism
|
5K23CA120862-03
|
$137,295
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$133,226
|
Ambs, Stefan
|
CCR (NCI)
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
1U01CA151452-01
|
$482,687
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Children's Oncology Group Statistics and Data Center Grant
|
3U10CA098413-08S1
|
$1,499,003
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Statistics and Data Center Grant
|
3U10CA098413-08S2
|
$39,636
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Children's Oncology Group Statistics and Data Center Grant
|
3U10CA098413-08S3
|
$39,636
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
SPORE in Myeloma
|
5P50CA100707-08
|
$2,300,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
|
5R01CA064475-15
|
$292,410
|
ANDERSON, CAROLYN
|
WASHINGTON UNIVERSITY
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-08
|
$5,935,261
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Mechanistic Targeting of Lung Cancer
|
ZIA BC 005399
|
$540,198
|
Anderson, Lucy
|
CCR (NCI)
|
|
Combined inhibition of CXCR4 and FLT3-ITD signaling in acute myeloid leukemia
|
1R21CA143805-01A1
|
$336,397
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
THE THERAPY OF AML
|
5P01CA055164-18
|
$2,483,417
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Biologic Therapy for B-cell non-Hodgkin's Lymphoma
|
5R01CA092104-07
|
$258,741
|
ANSELL, STEPHEN
|
MAYO CLINIC
|
|
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
|
5K24CA128953-03
|
$167,791
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Adult Leukemia Research Center
|
5P01CA018029-35
|
$4,628,534
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
SPORE in Breast Cancer
|
5P50CA098131-08
|
$2,190,230
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
Southeast Cancer Control Consortium, Inc
|
2U10CA045808-24
|
$2,264,660
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-12
|
$104,956
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Defining clinical efficacy and markers predicting response to bortezomib in AML
|
5K23CA118419-04
|
$143,370
|
Attar, Eyal
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Eastern Cooperative Oncology Group Studies
|
2U10CA014548-36
|
$420,754
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Purification of a Novel Antibody Against Solid Organ Cancer Stem Cells
|
ZIA BC 010997
|
$99,147
|
Avital, Itzhak
|
CCR (NCI)
|
|
Mechanism of Drug Transport in Lung Cancer Cells
|
5R01CA077495-12
|
$243,821
|
Awasthi, Sanjay
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma
|
4R44CA141936-02
|
$559,294
|
Babich, John
|
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
|
|
Nrf2 a new therapeutic target for human pancreatic ductal adenocarcinoma.
|
1R03CA152530-01
|
$76,750
|
BAE, INSOO
|
GEORGETOWN UNIVERSITY
|
|
ENGINEERED INTELLIGENT MICELLE FOR TUMOR pH TARGETING
|
5R01CA101850-06
|
$271,181
|
Bae, You
|
UNIVERSITY OF UTAH
|
|
Micelle surface engineering for active targeting by acidic tumor extracellular pH
|
5R01CA122356-05
|
$257,668
|
Bae, You
|
UNIVERSITY OF UTAH
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|